Mark litton athira
WebAthira Pharma, Inc. is a clinical-stage biopharmaceutical company. ... Mark J.Litton: 10/18/2024: 7/1/2024: Chief Financial Officer: GlennaMileson: 64: 1/1/2024: 10/1/2015: 8 additional Officers and Directors records available in full report. Business Names. Business Name; ATHA: Athira Pharma Australia PTY LTD: Web11 jul. 2024 · Athira, headquartered in Seattle, Washington, is a drug development company striving to improve human health by advancing new therapies for …
Mark litton athira
Did you know?
Web13 apr. 2024 · Mark Litton, CEO of Athira Pharma, a Washington-based biotech working to develop drugs for Alzheimer’s and other neurodegenerative diseases, told Healthcare Brew the company has been conservative with its cash and is hoping to have data next year. Web29 mrt. 2024 · “The progress we made throughout 2024 and in recent months continues to support our strategy to advance our small molecule therapeutic candidates, such as fosgonimeton, to impact neurodegenerative diseases,” Mark Litton, PhD, Athira’s president and CEO, said in the update.
Web18 jun. 2024 · Litton has acted in the role of COO since July 2024. Prior to joining Athira Pharma, his roles include serving as president and chief operating officer of Alpine … Web31 mrt. 2024 · Mark Litton took over as CEO of Athira Pharma in October, after former CEO Leen Kawas resigned. Athira Pharma Inc. (Nasdaq: ATHA) shareholder Ric …
Web21 mrt. 2024 · Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule for Alzheimer’s and Parkinson’s disease dementia and Dementia with Lewy bodies. For more information, visit www.athira.com. You can also follow Athira on Facebook , LinkedIn and @athirapharma on Twitter and Instagram. Web24 mrt. 2024 · Athira Pharma, Inc. (NASDAQ:ATHA) Q4 2024 Earnings Conference Call March 24, 2024 4:30 PM ET. Company Participants. Julie Rathbun - Investor Relations. …
Web8 okt. 2024 · At Athira, Dr. Litton has helped direct the company's Series B and initial public offering. During his tenure at Alder, he led the company's business operations and played a key role in the company's IPO, follow-on financings, collaborations, and partnerships.
Web27 jan. 2024 · On January 27, 2024, the Board, upon recommendation of the compensation committee of the Board, approved the Company's entry into an Amended and Restated Change in Control and Severance Agreement with Dr. Mark Litton , Athira's president and chief executive officer (the "Amended Litton Change in Control Agreement"). thelittlesquirrel.officialWeb8 feb. 2024 · Athira went public in 2024. “Our strong balance sheet, with cash of $339.4-million as of Sept. 30, 2024, will support our clinical programs through upcoming key inflection points,” Dr. Litton contends. Athira is currently evaluating ATH-1017 in the ACT-AD Phase 2 study in mild-to-moderate AD dementia. tickets for cheyenne mountain zooWeb30 mrt. 2024 · A billionaire investor of Athira Pharma is calling for the ouster of the Seattle company’s CEO and nominated himself and the former chief financial officer at Novartis … tickets for chicago auto show 2016Web5 apr. 2024 · Prior to his appointment as our President and Chief Executive Officer and as a director, Dr. Litton carried out the day-to-day responsibilities of President and CEO of Athira since June 2024, and served as our Chief Operating Officer since July 2024. the little spot booksWeb30 mrt. 2024 · To make matters worse, some of the academic credentials claimed by Dr. Litton in Athira’s SEC filings and website were false. Specifically, until just days ago, Dr. Litton claimed to have... tickets for chicago broadwayWeb21 okt. 2024 · Litton has demonstrated exemplary leadership of the Athira team since joining the Company in July 2024, and especially sinceassuming day-to-day leadership … the little spot of emotionWeb23 mrt. 2024 · Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to … tickets for chicago concert